Pliant Therapeutics PLRX Institutional Ownership

Updated Oct 11, 2026

Pliant Therapeutics, Inc. (NASDAQ:PLRX) was held by 86 institutional investors that filed 13F reports for the quarter ended June 30, 2026.

• Collectively, these holders controlled 77.68% of Pliant Therapeutics' outstanding shares in Q2 2026, up from 77.55% in Q1 2026.
• Total shares held in Pliant Therapeutics rose 0.18% versus Q1 2026, while the number of holders fell 22.52% versus Q2 2025.
• Of these 86 holders, 28 added to their positions, 25 reduced their stakes and 33 left their positions unchanged.
• Combined, institutional investors held 48.1Mn shares of PLRX as of Q2 2026, up 86.7K from the prior quarter and up 2.72Mn from a year earlier.
• Tang Capital Management LLC held the largest position in PLRX at 6.14Mn shares as of June 30, 2026, or 9.92% of shares outstanding.
• The largest position increases in PLRX for Q2 2026 were by ADAR1 Capital Management, LLC (+2.92Mn shares), Renaissance Technologies LLC (+197.03K shares), Verdad Advisers, LP (+183.02K shares), Geode Capital Management, LLC (+161.3K shares) and Vanguard Capital Management LLC (+97.25K shares).
• The largest position reductions in PLRX for Q2 2026 were by Citadel Advisors LLC (-1.08Mn shares), Millennium Management LLC (-621.07K shares), UBS Group AG (-486.19K shares), Goldman Sachs Group Inc (-388.25K shares) and Woodline Partners LP (-370.3K shares).
• Per Business Quant data, the 10 largest holders of Pliant Therapeutics at the end of Q2 2026 were Tang Capital Management LLC (6.14Mn shares), ADAR1 Capital Management, LLC (5.51Mn shares), Vanguard Capital Management LLC (2.44Mn shares), Acadian Asset Management LLC (2.42Mn shares), Two Sigma Investments, LP (2.26Mn shares), Citadel Advisors LLC (2.14Mn shares), Renaissance Technologies LLC (2.05Mn shares), Monaco Asset Management SAM (1.94Mn shares), Lynx1 Capital Management LP (1.8Mn shares) and BML Capital Management, LLC (1.55Mn shares).